کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3365429 1218367 2016 4 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment
ترجمه فارسی عنوان
خطر عوارض جانبی پوستی با درمان فبوکسوستات در بیماران با واکنش پوستی به آلوپورینول؛ یک مطالعه گذشته نگر، مبتنی بر بیمارستان از 101 بیمار تحت درمان آلوپورینول متوالی و فیبوکواستات
کلمات کلیدی
آلوپورینول؛ Febuxostat؛ نقرس؛ واکنش پذیری متقابل؛ واکنش پوستی؛ شدت عوارض جانبی پوستی (SCAR)
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی ایمونولوژی، آلرژی و روماتولوژی
چکیده انگلیسی

ObjectiveTo investigate the cutaneous tolerance of febuxostat in gouty patients with skin intolerance to allopurinol.MethodsWe identified all gouty patients who had sequentially received allopurinol and febuxostat in the rheumatology departments of 4 university hospitals in France and collected data from hospital files using a predefined protocol. Patients who had not visited the prescribing physician during at least 2 months after febuxostat prescription were excluded. The odds ratio (OR) for skin reaction to febuxostat in patients with a cutaneous reaction to allopurinol versus no reaction was calculated. For estimating the 95% confidence interval (95% CI), we used the usual Wald method and a bootstrap method.ResultsIn total, 113 gouty patients had sequentially received allopurinol and febuxostat; 12 did not visit the prescribing physician after febuxostat prescription and were excluded. Among 101 patients (86 males, mean age 61 ± 13.9 years), 2/22 (9.1%) with a history of cutaneous reactions to allopurinol showed skin reactions to febuxostat. Two of 79 patients (2.5%) without a skin reaction to allopurinol showed skin intolerance to febuxostat. The ORs were not statistically significant with the usual Wald method (3.85 [95% CI 0.51–29.04]) or bootstrap method (3.86 [95% CI 0.80–18.74]).ConclusionThe risk of skin reaction with febuxostat seems moderately increased in patients with a history of cutaneous adverse events with allopurinol. This moderate increase does not support the cross-reactivity of the two drugs.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Joint Bone Spine - Volume 83, Issue 3, May 2016, Pages 314–317
نویسندگان
, , , , , , , ,